Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Zacks Small Cap Research on MSN2d
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position ExpandsWINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...
Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Windtree Therapeutics (WINT) announced the initiation of enrollment in the SEISMiC C trial in SCAI Stage C cardiogenic shock. This study ...
The following is a summary of “Influence of Right and Left Bundle Branch Block in Patients With Cardiogenic Shock and Cardiac ...
PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical ...
Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated ... company focused on advancing early and late-stage innovative therapies for critical ...
By this stage the differential diagnosis had shifted ... typically present with hypotension, cardiomyopathy, or cardiogenic shock when β-adrenergic stimulation overrides α-adrenergic stimulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback